ATNM — Actinium Pharmaceuticals Inc

Actinium Pharmaceuticals Inc (ATNM) is a biotechnology company listed on AMEX. It is led by Sandesh C. Seth M.B.A., M.S., based in 100 Park Avenue, New York, NY, United States, 10017, with about 25 employees. Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. The company offers Actimab-A, a CD33 targeting radiotherapeutic for patients with Relapsed/Refractory AML which is in to a Phase 2/3 Trial; and Iomab-ACT, to improve patient access to and outcomes with cellular therapies, such as CAR-T and gene therapies for non-malignant hematologic disorders such as sickle cell disease. It also develops ATNM-400, a antibody radioconjugate that deliver alpha-emitter Ac-225 to prostate cancer cells. In addition, the company's Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia. Further, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies, and its research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company is based in New York, New York.

Latest reported ATNM revenue for 2025-09-30 was $90.0K. Net income was -$5.1M. ATNM currently screens at market cap $33.9M.

Use this ATNM page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the ATNM quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the ATNM SEC filings page. Lician reads the product cache first so this HTML stays unique to Actinium Pharmaceuticals Inc even when a live quote feed is slow.